Exelixis, Inc., a leading oncology-focused biotechnology firm, engages in the discovery, development, and commercialization of innovative therapeutic agents to treat various cancers in the United States. The weighted average number of diluted shares outstanding is 296,132,000.00 reflecting potential dilution effects from the company's equity structure. Among its portfolio, Exelixis markets CABOMETYX tablets, targeting advanced renal cell carcinoma patients who have undergone prior anti-angiogenic therapy, alongside COMETRIQ capsules designed for individuals with progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ are based on cabozantinib, an inhibitor that affects multiple tyrosine kinases such as MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, a MEK inhibitor used in combination therapies for advanced melanoma, and MINNEBRO, an oral mineralocorticoid receptor blocker for hypertension in Japan. The diluted EPS is $1.76 accounting for potential share dilution. Furthermore, Exelixis has reported an interest expense of $0.00 indicating its obligations related to debt servicing. The cost of revenue for the company is $76,216,000.00 showcasing its production and operational expenses, while the gross profit stands at $2,092,485,000.00 highlighting profitability from core operations. In addition, the company continues to develop promising candidates such as XL092, XB002, and XL102, targeting various oncological indications. Exelixis, Inc. actively engages in research collaborations and licensing agreements with numerous esteemed organizations, further strengthening its position in the oncology landscape. The company, which was originally known as Exelixis Pharmaceuticals, Inc. before rebranding in February 2000, has its roots dating back to its incorporation in 1994 in Alameda, California. The stock is affordable at $40.10 making it suitable for budget-conscious investors interested in a promising oncology-focused company. Furthermore, the stock has a high average trading volume of 2,687,385.00 indicating strong liquidity in the market. With a mid-range market capitalization of $11,877,434,075.00 Exelixis is a steady performer in its sector. It is a key player in the Biotechnology industry, significantly contributing to the overall market landscape through its innovative therapeutic solutions. Additionally, the company belongs to the Healthcare sector, consistently driving innovation and growth as it develops new treatments for cancer patients.